Michael C. Donegan is Prin. Fin. and Acctg. Officer at TherapeuticsMD, Inc. (TXMD). They have made 5 open-market trades across 1 company since 2021, most recently 2023-04-12.
CIK 0001627810
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TXMD | 61,853 | $113K |
Shares reported on the most recent Form 4, priced at the 2023-04-14 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TXMD | SELL | 2023-01-26 | 2023-01-30 | $5.08 | $9K | -3.9% | -5.2% | -34.0% |
| TXMD | SELL | 2023-01-23 | 2023-01-25 | $5.34 | $7K | -0.2% | -3.5% | -30.2% |
| TXMD | SELL | 2022-12-06 | 2022-12-09 | $4.78 | $4K | -4.8% | -17.1% | -32.2% |
| TXMD | SELL | 2021-11-30 | 2021-12-02 | $0.54 | $16K | -22.0% | -21.3% | -55.7% |
| TXMD | SELL | 2021-05-11 | 2021-05-12 | $1.04 | $5K | +18.4% | +28.2% | -10.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.